search
Back to results

A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine (ASCEND)

Primary Purpose

Migraine, Migraine With Aura, Migraine Without Aura

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Dihydroergotamine
Sponsored by
Satsuma Pharmaceuticals, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Migraine focused on measuring dihydroergotamine, dihydroergotamine mesylate, migraine

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

  • Males or females, 18-65 years of age at the time of Screening Visit
  • Subject has at least 1-year history of migraines (with or without aura), according to the
  • International Classification of Headache Disorder, 3rd Edition (ICHD3)

Key Exclusion Criteria:

  • Pregnant or breast-feeding women
  • Women of child-bearing potential not using or not willing to use highly effective contraception.
  • Diagnosis of headache conditions other than migraine with or without aura, including diagnosis of basilar or hemiplegic migraines or cluster headache.
  • History of coronary artery disease, coronary artery vasospasm (including Printz-metals' angina), clinically significant arrhythmia or, peripheral vascular disease, ischemic disease (e.g. Raynaud's syndrome, ischemic bowel syndrome, angina pectoris, myocardial infarction, or documented silent ischemia); percutaneous coronary intervention, or cardiac surgery.
  • History of cerebrovascular disease, including but not limited to stroke, transient ischemic attack, cerebral hemorrhage, subarachnoid hemorrhage.
  • Diagnosis of major depression with current symptoms, psychosis, alcohol abuse or dependence, drug abuse or dependence, major psychiatric conditions (e.g. schizophrenia, psychosis or Bipolar disorder), dementia. Other significant neurological or psychiatric disorders (including other pain syndromes or risk of suicide) that in the opinion of the investigator might interfere with study participation and assessments or subject safety.
  • Any clinically significant symptoms or conditions, including but not limited to central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions or history of such conditions that, in the opinion of the investigator might interfere with study assessments or safety of participant.

Sites / Locations

  • WR-PRI
  • Collaborative Neuroscience
  • WR-PRI
  • Downtown LA Research
  • Clinical Research Institute
  • WR-PRI
  • Hillcrest Medical Research
  • MD Clinical
  • Multi-Specialty Research Associates
  • ClinCloud
  • Behavioral Clinical Research
  • Biotech Pharmaceuticals
  • CNS Health Care - Orlando
  • Complete Health Research
  • Infinity Clinical Research
  • Santos Research Center, Corp
  • Palm Beach Research Center
  • Clinical Research CF
  • Advanced Clinical Research
  • Integrated Clinical Trial Services, Inc
  • Delricht Research
  • Medvadis Research at Boston PainCare Center
  • Healthcare Research Network
  • Clinvest Research
  • Montana Medical Research
  • Wake Research - Clinical Research Center of Nevada
  • Dartmouth-Hitchcock Neurology Headache Clinic
  • Hassman Research Institute
  • Albuquerque Clinical Trials
  • Montefiore Medical Center
  • SPRI Clinical Research
  • PharmQuest
  • PMG Research of Wilmington
  • CTI Clinical Research Center
  • Rapid Medical Research
  • Neurology Diagnosis
  • Delricht Research
  • Thomas Jefferson University/Jefferson Headache Center
  • Omega Medical Research
  • CNS Healthcare - Memphis
  • FutureSearch Trials of Neurology
  • DM Clinical Research
  • Charlottesville Medical Research
  • Georgetown University Hospital, Department of Neurology

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

STS101

Arm Description

STS101 (dihydroergotamine nasal powder)

Outcomes

Primary Outcome Measures

Percentage of Participants With Attacks With Sustained Freedom From Headache Pain 2-48 Hours (Modified Intent to Treat Population)
The subject's rating was documented on a four-point scale from no pain (= 0), mild pain (= 1), moderate pain (= 2) to severe pain (= 3). Pain freedom means the pain went from moderate (2) or severe (3) to no pain (0).
Percentage of Participants With Attacks With Sustained Freedom From Most Bothersome Symptom 2-48 Hours (Modified Intent to Treat Population)
Subjects were prompted to document the presence of 3 symptoms (photophobia, phonophobia, and nausea) immediately before study drug administration and during the treated migraine attack.

Secondary Outcome Measures

Full Information

First Posted
May 20, 2020
Last Updated
June 30, 2023
Sponsor
Satsuma Pharmaceuticals, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04406649
Brief Title
A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
Acronym
ASCEND
Official Title
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
September 14, 2020 (Actual)
Primary Completion Date
January 16, 2023 (Actual)
Study Completion Date
January 16, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Satsuma Pharmaceuticals, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Study STS101-003 is a multi-center, multiple dose (PRN), open-label, 12-month study to evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.
Detailed Description
The ASCEND trial is a multi-center, multiple dose (PRN), open-label, 12-month study to evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Migraine, Migraine With Aura, Migraine Without Aura
Keywords
dihydroergotamine, dihydroergotamine mesylate, migraine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
482 (Actual)

8. Arms, Groups, and Interventions

Arm Title
STS101
Arm Type
Experimental
Arm Description
STS101 (dihydroergotamine nasal powder)
Intervention Type
Drug
Intervention Name(s)
Dihydroergotamine
Other Intervention Name(s)
Dihydroergotamine Mesylate
Intervention Description
Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
Primary Outcome Measure Information:
Title
Percentage of Participants With Attacks With Sustained Freedom From Headache Pain 2-48 Hours (Modified Intent to Treat Population)
Description
The subject's rating was documented on a four-point scale from no pain (= 0), mild pain (= 1), moderate pain (= 2) to severe pain (= 3). Pain freedom means the pain went from moderate (2) or severe (3) to no pain (0).
Time Frame
At Month 12 of Study Medication Dosing
Title
Percentage of Participants With Attacks With Sustained Freedom From Most Bothersome Symptom 2-48 Hours (Modified Intent to Treat Population)
Description
Subjects were prompted to document the presence of 3 symptoms (photophobia, phonophobia, and nausea) immediately before study drug administration and during the treated migraine attack.
Time Frame
At Month 12 of Study Drug Administration

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: Males or females, 18-65 years of age at the time of Screening Visit Subject has at least 1-year history of migraines (with or without aura), according to the International Classification of Headache Disorder, 3rd Edition (ICHD3) Key Exclusion Criteria: Pregnant or breast-feeding women Women of child-bearing potential not using or not willing to use highly effective contraception. Diagnosis of headache conditions other than migraine with or without aura, including diagnosis of basilar or hemiplegic migraines or cluster headache. History of coronary artery disease, coronary artery vasospasm (including Printz-metals' angina), clinically significant arrhythmia or, peripheral vascular disease, ischemic disease (e.g. Raynaud's syndrome, ischemic bowel syndrome, angina pectoris, myocardial infarction, or documented silent ischemia); percutaneous coronary intervention, or cardiac surgery. History of cerebrovascular disease, including but not limited to stroke, transient ischemic attack, cerebral hemorrhage, subarachnoid hemorrhage. Diagnosis of major depression with current symptoms, psychosis, alcohol abuse or dependence, drug abuse or dependence, major psychiatric conditions (e.g. schizophrenia, psychosis or Bipolar disorder), dementia. Other significant neurological or psychiatric disorders (including other pain syndromes or risk of suicide) that in the opinion of the investigator might interfere with study participation and assessments or subject safety. Any clinically significant symptoms or conditions, including but not limited to central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions or history of such conditions that, in the opinion of the investigator might interfere with study assessments or safety of participant.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Detlef Albrecht, MD
Organizational Affiliation
Satsuma Pharmaceuticals, Inc.
Official's Role
Study Chair
Facility Information:
Facility Name
WR-PRI
City
Encino
State/Province
California
ZIP/Postal Code
91316
Country
United States
Facility Name
Collaborative Neuroscience
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Facility Name
WR-PRI
City
Los Alamitos
State/Province
California
ZIP/Postal Code
90720
Country
United States
Facility Name
Downtown LA Research
City
Los Angeles
State/Province
California
ZIP/Postal Code
90017
Country
United States
Facility Name
Clinical Research Institute
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
WR-PRI
City
Newport Beach
State/Province
California
ZIP/Postal Code
92660
Country
United States
Facility Name
Hillcrest Medical Research
City
DeLand
State/Province
Florida
ZIP/Postal Code
32720
Country
United States
Facility Name
MD Clinical
City
Hallandale Beach
State/Province
Florida
ZIP/Postal Code
33009
Country
United States
Facility Name
Multi-Specialty Research Associates
City
Lake City
State/Province
Florida
ZIP/Postal Code
32055
Country
United States
Facility Name
ClinCloud
City
Maitland
State/Province
Florida
ZIP/Postal Code
32751
Country
United States
Facility Name
Behavioral Clinical Research
City
Miami Lakes
State/Province
Florida
ZIP/Postal Code
33061
Country
United States
Facility Name
Biotech Pharmaceuticals
City
Miami
State/Province
Florida
ZIP/Postal Code
33155
Country
United States
Facility Name
CNS Health Care - Orlando
City
Orlando
State/Province
Florida
ZIP/Postal Code
32801
Country
United States
Facility Name
Complete Health Research
City
Ormond Beach
State/Province
Florida
ZIP/Postal Code
32174
Country
United States
Facility Name
Infinity Clinical Research
City
Sunrise
State/Province
Florida
ZIP/Postal Code
33351
Country
United States
Facility Name
Santos Research Center, Corp
City
Tampa
State/Province
Florida
ZIP/Postal Code
33615
Country
United States
Facility Name
Palm Beach Research Center
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33409
Country
United States
Facility Name
Clinical Research CF
City
Winter Haven
State/Province
Florida
ZIP/Postal Code
33880
Country
United States
Facility Name
Advanced Clinical Research
City
Meridian
State/Province
Idaho
ZIP/Postal Code
83642
Country
United States
Facility Name
Integrated Clinical Trial Services, Inc
City
West Des Moines
State/Province
Iowa
ZIP/Postal Code
50265
Country
United States
Facility Name
Delricht Research
City
Prairieville
State/Province
Louisiana
ZIP/Postal Code
70769
Country
United States
Facility Name
Medvadis Research at Boston PainCare Center
City
Waltham
State/Province
Massachusetts
ZIP/Postal Code
02451
Country
United States
Facility Name
Healthcare Research Network
City
Hazelwood
State/Province
Missouri
ZIP/Postal Code
63042
Country
United States
Facility Name
Clinvest Research
City
Springfield
State/Province
Missouri
ZIP/Postal Code
65810
Country
United States
Facility Name
Montana Medical Research
City
Missoula
State/Province
Montana
ZIP/Postal Code
59808
Country
United States
Facility Name
Wake Research - Clinical Research Center of Nevada
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89118
Country
United States
Facility Name
Dartmouth-Hitchcock Neurology Headache Clinic
City
Lebanon
State/Province
New Hampshire
ZIP/Postal Code
03766
Country
United States
Facility Name
Hassman Research Institute
City
Berlin
State/Province
New Jersey
ZIP/Postal Code
08009
Country
United States
Facility Name
Albuquerque Clinical Trials
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87102
Country
United States
Facility Name
Montefiore Medical Center
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Facility Name
SPRI Clinical Research
City
Brooklyn
State/Province
New York
ZIP/Postal Code
11235
Country
United States
Facility Name
PharmQuest
City
Greensboro
State/Province
North Carolina
ZIP/Postal Code
27408
Country
United States
Facility Name
PMG Research of Wilmington
City
Wilmington
State/Province
North Carolina
ZIP/Postal Code
28401
Country
United States
Facility Name
CTI Clinical Research Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45212
Country
United States
Facility Name
Rapid Medical Research
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44122
Country
United States
Facility Name
Neurology Diagnosis
City
Dayton
State/Province
Ohio
ZIP/Postal Code
45459
Country
United States
Facility Name
Delricht Research
City
Tulsa
State/Province
Oklahoma
ZIP/Postal Code
74133
Country
United States
Facility Name
Thomas Jefferson University/Jefferson Headache Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Omega Medical Research
City
Warwick
State/Province
Rhode Island
ZIP/Postal Code
02886
Country
United States
Facility Name
CNS Healthcare - Memphis
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38119
Country
United States
Facility Name
FutureSearch Trials of Neurology
City
Austin
State/Province
Texas
ZIP/Postal Code
78731
Country
United States
Facility Name
DM Clinical Research
City
Tomball
State/Province
Texas
ZIP/Postal Code
77375
Country
United States
Facility Name
Charlottesville Medical Research
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22911
Country
United States
Facility Name
Georgetown University Hospital, Department of Neurology
City
McLean
State/Province
Virginia
ZIP/Postal Code
22101
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine

We'll reach out to this number within 24 hrs